Axovant Announced Administration of AXO-Lenti-PD, A Novel Gene Therapy for Patient’s with Parkinson’s Disease, to First Patient in Clinical Study

October 25, 2018 — Axovant announced that the first patient in a clinical study was administered dosing of AXO-Lenti-PD, which is an investigational gene therapy to treat Parkinson’s disease, that enables the expression of a set of three critical enzymes needed for end-to-end dopamine synthesis in the brain. For the full article, please visit Axovant’s website.
Read More

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

This month is? (Anti-Spam)

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2020 The Parkinson Alliance. All rights reserved.